MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.960
-0.110
-3.58%
After Hours: 2.800 -0.16 -5.41% 18:32 05/15 EDT
OPEN
3.060
PREV CLOSE
3.070
HIGH
3.140
LOW
2.860
VOLUME
59.48K
TURNOVER
--
52 WEEK HIGH
19.63
52 WEEK LOW
1.760
MARKET CAP
8.14M
P/E (TTM)
-0.2715
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCSA last week (0504-0508)?
Weekly Report · 5d ago
Processa Pharmaceuticals Q1 net loss widens to $3.38 million
PUBT · 05/07 21:25
Weekly Report: what happened at PCSA last week (0427-0501)?
Weekly Report · 05/04 09:50
Processa R&D President David Young acquires 1,706 shares for $4,589.14
PUBT · 05/01 20:40
Processa CFO Russell Skibsted buys 2,190 shares worth $5,891.1
PUBT · 05/01 20:39
Processa CEO George Ng acquires $5,472.46 of common shares
PUBT · 05/01 20:38
Processa Chief Business-Strategy Officer Patrick Lin buys 1,511 shares for $4,065.59
PUBT · 05/01 20:37
Processa CAO Wendy Guy buys 1,748 shares for $4,704.12
PUBT · 05/01 20:36
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.